SGMO vs. CRIS, AGEN, SABS, ALVR, VIGL, PLX, ATRA, BLUE, OTLK, and BCAB
Should you be buying Sangamo Therapeutics stock or one of its competitors? The main competitors of Sangamo Therapeutics include Curis (CRIS), Agenus (AGEN), SAB Biotherapeutics (SABS), AlloVir (ALVR), Vigil Neuroscience (VIGL), Protalix BioTherapeutics (PLX), Atara Biotherapeutics (ATRA), bluebird bio (BLUE), Outlook Therapeutics (OTLK), and BioAtla (BCAB). These companies are all part of the "biological products, except diagnostic" industry.
Sangamo Therapeutics (NASDAQ:SGMO) and Curis (NASDAQ:CRIS) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their community ranking, dividends, analyst recommendations, risk, earnings, profitability, institutional ownership, media sentiment and valuation.
In the previous week, Sangamo Therapeutics had 2 more articles in the media than Curis. MarketBeat recorded 4 mentions for Sangamo Therapeutics and 2 mentions for Curis. Sangamo Therapeutics' average media sentiment score of 0.29 beat Curis' score of 0.00 indicating that Sangamo Therapeutics is being referred to more favorably in the media.
Curis received 246 more outperform votes than Sangamo Therapeutics when rated by MarketBeat users. Likewise, 67.52% of users gave Curis an outperform vote while only 62.66% of users gave Sangamo Therapeutics an outperform vote.
Curis has lower revenue, but higher earnings than Sangamo Therapeutics. Curis is trading at a lower price-to-earnings ratio than Sangamo Therapeutics, indicating that it is currently the more affordable of the two stocks.
Sangamo Therapeutics has a beta of 1.4, indicating that its share price is 40% more volatile than the S&P 500. Comparatively, Curis has a beta of 3.59, indicating that its share price is 259% more volatile than the S&P 500.
56.9% of Sangamo Therapeutics shares are held by institutional investors. Comparatively, 30.0% of Curis shares are held by institutional investors. 2.8% of Sangamo Therapeutics shares are held by insiders. Comparatively, 5.7% of Curis shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Sangamo Therapeutics has a net margin of -146.30% compared to Curis' net margin of -473.04%. Sangamo Therapeutics' return on equity of -82.17% beat Curis' return on equity.
Sangamo Therapeutics currently has a consensus price target of $5.67, indicating a potential upside of 919.55%. Curis has a consensus price target of $37.33, indicating a potential upside of 128.20%. Given Sangamo Therapeutics' higher probable upside, equities analysts clearly believe Sangamo Therapeutics is more favorable than Curis.
Summary
Sangamo Therapeutics beats Curis on 9 of the 17 factors compared between the two stocks.
Get Sangamo Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for SGMO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SGMO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Sangamo Therapeutics Competitors List
Related Companies and Tools
